These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25000660)

  • 1. [Case report of introducing MMF and steroids as an immunosuppressive therapy after living-donor liver transplantation for a patient with the diabetic nephropathy].
    Kuramitsu S; Iguchi T; Ninomiya M; Yamashita Y; Harimoto N; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Shirabe K; Kawanaka H; Ikeda T; Furuta T; Tamada R; Maehara Y
    Fukuoka Igaku Zasshi; 2014 Mar; 105(3):79-83. PubMed ID: 25000660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation.
    Jain A; Mohanka R; Orloff M; Abt P; Kashyap R; Kelley M; Burlee K; Bozorgzadeh A
    Exp Clin Transplant; 2005 Dec; 3(2):361-5. PubMed ID: 16417444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.
    Jain A; Sharma R; Ryan C; Tsoulfas G; Orloff M; Abt P; Kashyap R; Batzold P; Sauberman L; Safadjou S; Graham M; Bozorgzadeh A
    Liver Transpl; 2008 Feb; 14(2):202-9. PubMed ID: 18236395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
    Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
    Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
    Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.
    Biselli M; Vitale G; Gramenzi A; Riili A; Berardi S; Cammà C; Scuteri A; Morelli MC; Grazi GL; Pinna AD; Andreone P; Bernardi M
    Clin Transplant; 2009; 23(2):191-8. PubMed ID: 19210525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin-inhibitor-sparing immunosuppressive protocols.
    Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor minimization protocols in liver transplantation.
    Farkas SA; Schnitzbauer AA; Kirchner G; Obed A; Banas B; Schlitt HJ
    Transpl Int; 2009 Jan; 22(1):49-60. PubMed ID: 19121146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report.
    Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M
    Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mycophenolate mofetil-based calcineurin inhibitor reduced immunosuppressive protocol for the improvement of renal dysfunction after liver transplantation].
    Lai W; Lu SC; Wang ML; Zhang J; Wu JS; Dai J; Zeng DB; Xia RP; Li N
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1529-32. PubMed ID: 19953878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
    Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
    Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
    Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients.
    Mourer JS; Ewe SH; Mallat MJ; Ng AC; Rabelink TJ; Bax JJ; Delgado V; de Fijter JW
    Transplantation; 2012 Oct; 94(7):721-8. PubMed ID: 22955227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-induction renal sparing approach after liver transplantation: high dose mycophenolate mofetil with delayed, low-dose tacrolimus.
    Rao V; Haywood S; Abecassis M; Levitsky J
    Transplant Proc; 2013; 45(1):320-2. PubMed ID: 23267806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.